EMEA (Europe, Middle East and Africa) Anti-Obesity Prescription Drugs Market Report 2017

December 2017 | 106 pages | ID: ECDF8075905EN
QYResearch

Abstracts

In this report, the EMEA Anti-Obesity Prescription Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Anti-Obesity Prescription Drugs for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Anti-Obesity Prescription Drugs market competition by top manufacturers/players, with Anti-Obesity Prescription Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• VIVUS
• Orexigen Therapeutics
• Novo Nordisk
• F Hoffmann La Roche
• Arena Pharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Bupropion and Naltrexone
• Orlistat
• Lorcaserin
• Phentermine and Topiramate
• Liraglutide

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospitals Pharmacies
• Retail Pharmacies
• E-commerce

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Anti-Obesity Prescription Drugs Market Report 2017

1 ANTI-OBESITY PRESCRIPTION DRUGS OVERVIEW

1.1 Product Overview and Scope of Anti-Obesity Prescription Drugs
1.2 Classification of Anti-Obesity Prescription Drugs
  1.2.1 EMEA Anti-Obesity Prescription Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Anti-Obesity Prescription Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Bupropion and Naltrexone
  1.2.4 Orlistat
  1.2.5 Lorcaserin
  1.2.6 Phentermine and Topiramate
  1.2.7 Liraglutide
1.3 EMEA Anti-Obesity Prescription Drugs Market by Application/End Users
  1.3.1 EMEA Anti-Obesity Prescription Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospitals Pharmacies
  1.3.3 Retail Pharmacies
  1.3.4 E-commerce
1.4 EMEA Anti-Obesity Prescription Drugs Market by Region
  1.4.1 EMEA Anti-Obesity Prescription Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Anti-Obesity Prescription Drugs (2012-2022)
  1.5.1 EMEA Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2022)

2 EMEA ANTI-OBESITY PRESCRIPTION DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Anti-Obesity Prescription Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Anti-Obesity Prescription Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Anti-Obesity Prescription Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Anti-Obesity Prescription Drugs Sale Price by Players (2012-2017)
2.2 EMEA Anti-Obesity Prescription Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Anti-Obesity Prescription Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Anti-Obesity Prescription Drugs Sale Price by Type (2012-2017)
2.3 EMEA Anti-Obesity Prescription Drugs (Volume) by Application
2.4 EMEA Anti-Obesity Prescription Drugs (Volume and Value) by Region
  2.4.1 EMEA Anti-Obesity Prescription Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Anti-Obesity Prescription Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Anti-Obesity Prescription Drugs Sales Price by Region (2012-2017)

3 EUROPE ANTI-OBESITY PRESCRIPTION DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Anti-Obesity Prescription Drugs Sales and Value (2012-2017)
  3.1.1 Europe Anti-Obesity Prescription Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Anti-Obesity Prescription Drugs Sales and Market Share by Type
3.3 Europe Anti-Obesity Prescription Drugs Sales and Market Share by Application
3.4 Europe Anti-Obesity Prescription Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Anti-Obesity Prescription Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Anti-Obesity Prescription Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Anti-Obesity Prescription Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Anti-Obesity Prescription Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Anti-Obesity Prescription Drugs Sales and Market Share by Type
4.3 Middle East Anti-Obesity Prescription Drugs Sales and Market Share by Application
4.4 Middle East Anti-Obesity Prescription Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Anti-Obesity Prescription Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Anti-Obesity Prescription Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)

5 AFRICA ANTI-OBESITY PRESCRIPTION DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Anti-Obesity Prescription Drugs Sales and Value (2012-2017)
  5.1.1 Africa Anti-Obesity Prescription Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Anti-Obesity Prescription Drugs Sales and Market Share by Type
5.3 Africa Anti-Obesity Prescription Drugs Sales and Market Share by Application
5.4 Africa Anti-Obesity Prescription Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Anti-Obesity Prescription Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Anti-Obesity Prescription Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2017)

6 EMEA ANTI-OBESITY PRESCRIPTION DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 VIVUS
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 VIVUS Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Orexigen Therapeutics
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Novo Nordisk
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Novo Nordisk Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 F Hoffmann La Roche
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Arena Pharmaceuticals
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Anti-Obesity Prescription Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview

7 ANTI-OBESITY PRESCRIPTION DRUGS MANUFACTURING COST ANALYSIS

7.1 Anti-Obesity Prescription Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Anti-Obesity Prescription Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Anti-Obesity Prescription Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Anti-Obesity Prescription Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA ANTI-OBESITY PRESCRIPTION DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Anti-Obesity Prescription Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Anti-Obesity Prescription Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Anti-Obesity Prescription Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Anti-Obesity Prescription Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Anti-Obesity Prescription Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Anti-Obesity Prescription Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Anti-Obesity Prescription Drugs
Figure EMEA Anti-Obesity Prescription Drugs Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Anti-Obesity Prescription Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Bupropion and Naltrexone Product Picture
Figure Orlistat Product Picture
Figure Lorcaserin Product Picture
Figure Phentermine and Topiramate Product Picture
Figure Liraglutide Product Picture
Figure EMEA Anti-Obesity Prescription Drugs Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Anti-Obesity Prescription Drugs by Application in 2016
Figure Hospitals Pharmacies Examples
Table Key Downstream Customer in Hospitals Pharmacies
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure E-commerce Examples
Table Key Downstream Customer in E-commerce
Figure EMEA Anti-Obesity Prescription Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Anti-Obesity Prescription Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Anti-Obesity Prescription Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Anti-Obesity Prescription Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Anti-Obesity Prescription Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Anti-Obesity Prescription Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Sales Share by Players (2012-2017)
Figure 2016 Anti-Obesity Prescription Drugs Sales Share by Players
Figure 2017 Anti-Obesity Prescription Drugs Sales Share by Players
Figure EMEA Anti-Obesity Prescription Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Anti-Obesity Prescription Drugs Revenue Share by Players
Table 2017 EMEA Anti-Obesity Prescription Drugs Revenue Share by Players
Table EMEA Anti-Obesity Prescription Drugs Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Anti-Obesity Prescription Drugs by Type (2012-2017)
Figure EMEA Anti-Obesity Prescription Drugs Sales Market Share by Type (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Anti-Obesity Prescription Drugs by Type in 2016
Table EMEA Anti-Obesity Prescription Drugs Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Anti-Obesity Prescription Drugs by Application (2012-2017)
Figure EMEA Anti-Obesity Prescription Drugs Sales Market Share by Application in 2016
Table EMEA Anti-Obesity Prescription Drugs Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Anti-Obesity Prescription Drugs by Region (2012-2017)
Figure EMEA Anti-Obesity Prescription Drugs Sales Market Share in 2016
Table EMEA Anti-Obesity Prescription Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Anti-Obesity Prescription Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Anti-Obesity Prescription Drugs by Region (2012-2017)
Figure EMEA Anti-Obesity Prescription Drugs Revenue Market Share Regions in 2016
Table EMEA Anti-Obesity Prescription Drugs Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2017)
Table Europe Anti-Obesity Prescription Drugs Sales (K Units) by Type (2012-2017)
Table Europe Anti-Obesity Prescription Drugs Market Share by Type (2012-2017)
Figure Europe Anti-Obesity Prescription Drugs Market Share by Type in 2016
Table Europe Anti-Obesity Prescription Drugs Sales (K Units) by Application (2012-2017)
Table Europe Anti-Obesity Prescription Drugs Market Share by Application (2012-2017)
Figure Europe Anti-Obesity Prescription Drugs Market Share by Application in 2016
Table Europe Anti-Obesity Prescription Drugs Sales (K Units) by Countries (2012-2017)
Table Europe Anti-Obesity Prescription Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Anti-Obesity Prescription Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Anti-Obesity Prescription Drugs Sales Market Share by Countries in 2016
Table Europe Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Anti-Obesity Prescription Drugs Revenue Market Share by Countries in 2016
Figure Germany Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure France Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UK Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Anti-Obesity Prescription Drugs Sales (K Units) by Type (2012-2017)
Table Middle East Anti-Obesity Prescription Drugs Market Share by Type (2012-2017)
Figure Middle East Anti-Obesity Prescription Drugs Market Share by Type (2012-2017)
Table Middle East Anti-Obesity Prescription Drugs Sales (K Units) by Applications (2012-2017)
Table Middle East Anti-Obesity Prescription Drugs Market Share by Applications (2012-2017)
Figure Middle East Anti-Obesity Prescription Drugs Sales Market Share by Application in 2016
Table Middle East Anti-Obesity Prescription Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Anti-Obesity Prescription Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Anti-Obesity Prescription Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Anti-Obesity Prescription Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Anti-Obesity Prescription Drugs Sales (K Units) by Type (2012-2017)
Table Africa Anti-Obesity Prescription Drugs Sales Market Share by Type (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Sales Market Share by Type (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Sales Market Share by Type in 2016
Table Africa Anti-Obesity Prescription Drugs Sales (K Units) by Application (2012-2017)
Table Africa Anti-Obesity Prescription Drugs Sales Market Share by Application (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Sales Market Share by Application (2012-2017)
Table Africa Anti-Obesity Prescription Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Africa Anti-Obesity Prescription Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Sales Market Share by Countries in 2016
Table Africa Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Anti-Obesity Prescription Drugs Revenue Market Share by Countries in 2016
Figure South Africa Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Table VIVUS Anti-Obesity Prescription Drugs Basic Information List
Table VIVUS Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Sales Market Share in EMEA (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Revenue Market Share in EMEA (2012-2017)
Table Orexigen Therapeutics Anti-Obesity Prescription Drugs Basic Information List
Table Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales Market Share in EMEA (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue Market Share in EMEA (2012-2017)
Table Novo Nordisk Anti-Obesity Prescription Drugs Basic Information List
Table Novo Nordisk Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Sales Market Share in EMEA (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Revenue Market Share in EMEA (2012-2017)
Table F Hoffmann La Roche Anti-Obesity Prescription Drugs Basic Information List
Table F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales Market Share in EMEA (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Revenue Market Share in EMEA (2012-2017)
Table Arena Pharmaceuticals Anti-Obesity Prescription Drugs Basic Information List
Table Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales Market Share in EMEA (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Anti-Obesity Prescription Drugs
Figure Manufacturing Process Analysis of Anti-Obesity Prescription Drugs
Figure Anti-Obesity Prescription Drugs Industrial Chain Analysis
Table Raw Materials Sources of Anti-Obesity Prescription Drugs Major Manufacturers in 2016
Table Major Buyers of Anti-Obesity Prescription Drugs
Table Distributors/Traders List
Figure EMEA Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Anti-Obesity Prescription Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Anti-Obesity Prescription Drugs Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Anti-Obesity Prescription Drugs Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Anti-Obesity Prescription Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Anti-Obesity Prescription Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Anti-Obesity Prescription Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Anti-Obesity Prescription Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Anti-Obesity Prescription Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Anti-Obesity Prescription Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Anti-Obesity Prescription Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Anti-Obesity Prescription Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Anti-Obesity Prescription Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Anti-Obesity Prescription Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Anti-Obesity Prescription Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Anti-Obesity Prescription Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Anti-Obesity Prescription Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Anti-Obesity Prescription Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Anti-Obesity Prescription Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Anti-Obesity Prescription Drugs Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Anti-Obesity Prescription Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Anti-Obesity Prescription Drugs Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Anti-Obesity Prescription Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources